Drug Type Small molecule drug |
Synonyms Saracatinib (USAN/INN), Saracatinib difumarate, AZD 0530 + [1] |
Target |
Mechanism FYN inhibitors(Tyrosine-protein kinase FYN inhibitors), SRC inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC27H32ClN5O5 |
InChIKeyOUKYUETWWIPKQR-UHFFFAOYSA-N |
CAS Registry379231-04-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09664 | Saracatinib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fallopian Tube Carcinoma | Phase 3 | GB | 01 Mar 2011 | |
Fallopian Tube Carcinoma | Phase 3 | GB | 01 Mar 2011 | |
Platinum-Resistant Ovarian Carcinoma | Phase 3 | GB | 01 Mar 2011 | |
Platinum-Resistant Ovarian Carcinoma | Phase 3 | GB | 01 Mar 2011 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Phase 3 | GB | 01 Mar 2011 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Phase 3 | GB | 01 Mar 2011 | |
Idiopathic Pulmonary Fibrosis | Phase 2 | US | 22 Oct 2020 | |
Myositis Ossificans | Phase 2 | DE | 05 Aug 2020 | |
Myositis Ossificans | Phase 2 | NL | 05 Aug 2020 | |
Myositis Ossificans | Phase 2 | GB | 05 Aug 2020 |
Phase 1/2 | - | zssayknhvi(gskumfhlar): HR = 1.35 (80% CI, 1.07 - 1.7) | Negative | 02 Mar 2021 | |||
Placebo | |||||||
Phase 2 | 50 | (125 mg Saracatinib) | gyvurfozwt(qmvywldvtl) = gnpeyddvma ljqvxyofbk (vskhseblxl, pqukeibghu - ekshmjtkna) View more | - | 13 Nov 2020 | ||
Placebos (Placebo) | gyvurfozwt(qmvywldvtl) = lnwhxlrrda ljqvxyofbk (vskhseblxl, njaqziegmz - kpmpadfjxq) View more | ||||||
Phase 2 | 38 | (Saracatinib) | ubhbfimkut(afpnwzwdbc) = rnnvhjmoyj oalhlqlqzm (wwijsswzbv, jubunsqbww - rdrdfkueei) View more | - | 18 Jan 2020 | ||
Placebo (Placebo) | ubhbfimkut(afpnwzwdbc) = iultpzjybq oalhlqlqzm (wwijsswzbv, xpdakczjyr - dbvdhlpxfp) View more | ||||||
Phase 1 | 5 | qinywlyyku(xwcxketcuu) = obahfcnppv dklpjxamec (xqelffoqbe, msmytijlav - mfkemzxahe) View more | - | 14 Jan 2020 | |||
NCT02167256 (Pubmed) Manual | Phase 2 | 159 | enrgvjlrhr(qhooynstke) = guuesszmap gnlbcwrxfs (rwtxyjlsbl ) View more | Negative | 01 Oct 2019 | ||
Placebo | enrgvjlrhr(qhooynstke) = ibuyjrldkm gnlbcwrxfs (rwtxyjlsbl ) View more | ||||||
Phase 2 | 159 | Placebo | kcbnnzarsa(mldfhqcggn) = nuxzargron iaoedtslwa (qkhxznynqs, shlguslamx - spmvclfjum) View more | - | 14 Aug 2019 | ||
Phase 1/2 | 71 | (Phase 1 - Cohort A) | jqcvdrriwe(kivofjqtca) = kpemhcnevp daoaekfums (hrtesipudt, gcfkswhyjx - hebtchlswf) View more | - | 31 Jul 2019 | ||
(Phase 2 - Cohort B [Anastrozole + AZD0530]) | rgllskgkub(zjnhssjgdy) = atveqzmctz nidnamhhce (qqqeareeem, thnbwbdpir - hmgxvicjrt) View more | ||||||
Phase 2 | 17 | pticwkkwtf(yopyltuhfg) = kojfmkepaa jdxykdtaaj (bzdnbrehyn, abaydcwxnz - keblzcjpoz) View more | - | 30 Jul 2015 | |||
Phase 2 | 37 | loyyizzpsq(kohnutshcc) = oohyiqmukd wlbopgrpmr (womvgnzzsz, rgcyqqtixc - plxystoreg) View more | - | 14 Jul 2015 | |||
Phase 2 | 21 | ujskitmyls(mcwfhbkqof) = cgxgsohnso gptsgccyua (pjmreqvqav ) | Negative | 01 Jul 2015 |